| PharmacoGx: an R package for analysis of large pharmacogenomic datasets P Smirnov, Z Safikhani, N El-Hachem, D Wang, A She, C Olsen, ... Bioinformatics 32 (8), 1244-1246, 2016 | 153 | 2016 |
| PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies P Smirnov, V Kofia, A Maru, M Freeman, C Ho, N El-Hachem, GA Adam, ... Nucleic acids research 46 (D1), D994-D1002, 2018 | 92 | 2018 |
| Dr. VAE: improving drug response prediction via modeling of drug perturbation effects L Rampášek, D Hidru, P Smirnov, B Haibe-Kains, A Goldenberg Bioinformatics 35 (19), 3743-3751, 2019 | 85* | 2019 |
| Revisiting inconsistency in large pharmacogenomic studies Z Safikhani, P Smirnov, M Freeman, N El-Hachem, A She, Q Rene, ... F1000Research 5, 2016 | 72 | 2016 |
| Machine learning approaches to drug response prediction: challenges and recent progress G Adam, L Rampášek, Z Safikhani, P Smirnov, B Haibe-Kains, ... NPJ precision oncology 4 (1), 1-10, 2020 | 50 | 2020 |
| Gene isoforms as expression-based biomarkers predictive of drug response in vitro Z Safikhani, P Smirnov, KL Thu, J Silvester, N El-Hachem, R Quevedo, ... Nature communications 8 (1), 1-11, 2017 | 44 | 2017 |
| Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer KL Thu, J Silvester, MJ Elliott, W Ba-Alawi, MH Duncan, AC Elia, AS Mer, ... Proceedings of the National Academy of Sciences 115 (7), E1570-E1577, 2018 | 39 | 2018 |
| Integrative cancer pharmacogenomics to infer large-scale drug taxonomy N El-Hachem, DMA Gendoo, LS Ghoraie, Z Safikhani, P Smirnov, ... Cancer research 77 (11), 3057-3069, 2017 | 32 | 2017 |
| Assessment of pharmacogenomic agreement Z Safikhani, N El-Hachem, R Quevedo, P Smirnov, A Goldenberg, ... F1000Research 5, 2016 | 30 | 2016 |
| Tissue specificity of in vitro drug sensitivity F Yao, SA Madani Tonekaboni, Z Safikhani, P Smirnov, N El-Hachem, ... Journal of the American Medical Informatics Association 25 (2), 158-166, 2018 | 18 | 2018 |
| Modeling cellular response in large-scale radiogenomic databases to advance precision radiotherapy VSK Manem, M Lambie, I Smith, P Smirnov, V Kofia, M Freeman, ... Cancer research 79 (24), 6227-6237, 2019 | 17 | 2019 |
| Safikhani et al. reply Z Safikhani, N El-Hachem, P Smirnov, M Freeman, A Goldenberg, ... Nature 540 (7631), E2-E4, 2016 | 16 | 2016 |
| Integrative pharmacogenomics analysis of patient-derived xenografts AS Mer, W Ba-Alawi, P Smirnov, YX Wang, B Brew, J Ortmann, MS Tsao, ... Cancer research 79 (17), 4539-4550, 2019 | 15 | 2019 |
| Design of a HIFU array for the treatment of deep venous thrombosis: a simulation study P Smirnov, K Hynynen Physics in Medicine & Biology 62 (15), 6108, 2017 | 9 | 2017 |
| Personalized diagnosis of medulloblastoma subtypes across patients and model systems DMA Gendoo, P Smirnov, M Lupien, B Haibe-Kains Genomics 106 (2), 96-106, 2015 | 9 | 2015 |
| Stochastic combinatorial ensembles for defending against adversarial examples GA Adam, P Smirnov, D Duvenaud, B Haibe-Kains, A Goldenberg arXiv preprint arXiv:1808.06645, 2018 | 7 | 2018 |
| The mevalonate pathway is an actionable vulnerability of t (4; 14)-positive multiple myeloma J Longo, P Smirnov, Z Li, E Branchard, JE van Leeuwen, JD Licht, ... Leukemia 35 (3), 796-808, 2021 | 6 | 2021 |
| Consistency in drug response profiling Reply Z Safikhani, N El-Hachem, P Smirnov, M Freeman, A Goldenberg, ... Nature, E6-E8, 2016 | 4 | 2016 |
| Orchestrating and sharing large multimodal data for transparent and reproducible research A Mammoliti, P Smirnov, M Nakano, Z Safikhani, C Eeles, H Seo, SK Nair, ... Nature communications 12 (1), 1-10, 2021 | 3 | 2021 |
| Assessment of genetic drift in large pharmacogenomic studies R Quevedo, P Smirnov, D Tkachuk, C Ho, N El-Hachem, Z Safikhani, ... Cell Systems 11 (4), 393-401. e2, 2020 | 3 | 2020 |
Benjamin Haibe-KainsScientist (Principal Investigator), Princess Margaret Cancer Centre, University Health NetworkVerified email at uhnresearch.ca
